Mielóma multiplex: vizsgálatok itt: Hollandia
31 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 1. fázisTaking peopleStudy of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Amsterdam, Rotterdam, Utrecht
- Életkor
- 18 év and over
- People
- 135 worldwide
- Run by
- AbbVie
See details and how to joinNCT06896916 · EU 2024-512146-41-00 - 3. fázisNot yet taking people in HollandiaA study investigating the safety and efficacy of academically-produced CAR T cells compared with standard treatment for patients with multiple myeloma whose disease has returned or not responded to previous treatments.
- Where
- Groningen
- Életkor
- 18 év and over
- People
- 126
- Run by
- Universitair Medisch Centrum Groningen
See details and how to join2025-524876-43-00 - 2. fázisTaking peopleStudy for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
- Where
- Amsterdam, Arnhem, Enschede, Geleen, Groningen, Nieuwegein, Rotterdam, 's-Gravenhage, Zwolle
- Életkor
- 18 év and over
- People
- 150 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to joinNCT07107529 · EU 2024-520433-76-00 - 3. fázisTaking peopleA Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
- Where
- Rotterdam
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to joinNCT06932562 · EU 2024-519827-16-00 - 1/2. fázisTaking peopleLUMC-BOB1-B7-TCR.1 in relapsed and refractory B-cell malignancies
- Where
- Leiden
- Életkor
- 18 év and over
- People
- 22
- Run by
- Leids Universitair Medisch Centrum (LUMC)
See details and how to join2024-515900-38-00 - 3. fázisTaking peopleFeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)
- Where
- Alkmaar, Almelo, Almere, Amersfoort, Amstelveen, Amsterdam, Apeldoorn, Arnhem, Assen, Beugen, Beverwijk, Breda, Capelle aan den IJssel, Delft, Deventer, Dirksland, Doetinchem, Dordrecht, Drachten, Ede Gld, Eindhoven, Emmen, Enschede, Geldrop, Geleen, Goes, Gorinchem, Gouda, Groningen, Hardenberg, Harderwijk, Heerenveen, Helmond, Hilversum, Hoofddorp, Hoorn Nh, Leeuwarden, Leiderdorp, Maastricht, Nieuwegein, Nijmegen, Roermond, Roosendaal, Rotterdam, Scheemda, Schiedam, 's-Gravenhage, 's-Hertogenbosch, Sneek, Terneuzen, Tiel, Tilburg, Uden, Utrecht, Venlo, Zaandam, Zwolle, St. Jans Gasthuis
- Életkor
- 18 év and over
- People
- 599
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT06187441 · EU 2023-508586-33-00